newsfilter
← Latest News
Business Wire·

Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022

-- MGTA-117 Phase 1/2 clinical trial is open for enrollment for patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes; clinical data expected in 2022 –- -- CD45 antibody drug conjugate is Magenta's second conditio